Valneva SE (EPA:VLA)
2.414
+0.034 (1.43%)
Apr 28, 2026, 5:35 PM CET
Valneva SE Revenue
In the year 2025, Valneva SE had annual revenue of 174.66M EUR with 3.00% growth. Valneva SE had revenue of 47.69M in the quarter ending December 31, 2025, a decrease of -9.92%.
Revenue
174.66M
Revenue Growth
+3.00%
P/S Ratio
2.40
Revenue / Employee
259.14K
Employees
674
Market Cap
419.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 174.66M | 5.08M | 3.00% |
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genfit | 65.43M |
| Cellectis | 67.79M |
| Transgene | 7.21M |
| MedinCell | 32.44M |
| Sensorion | 5.81M |
| Inventiva | 6.76M |
| DBV Technologies | 4.80M |
| ABIONYX Pharma | 4.10M |
Valneva SE News
- 4 hours ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - GlobeNewsWire
- 7 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewsWire
- 12 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 25 days ago - Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewsWire
- 4 weeks ago - Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC - GlobeNewsWire
- 5 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewsWire
- 5 weeks ago - Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges - GuruFocus
- 5 weeks ago - An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive - WSJ